May 13, 2020 / 11:31 AM / 16 days ago

BRIEF-Vanda Pharmaceuticals- Reached Agreement With FDA To Resubmit Application For Hetlioz To Treat Patients With Smith-Magenis Syndrome

May 13 (Reuters) - Vanda Pharmaceuticals Inc:

* VANDA PHARMACEUTICALS ANNOUNCES AGREEMENT WITH FDA ON RESUBMISSION OF THE APPLICATION FOR HETLIOZ® FOR THE TREATMENT OF PATIENTS WITH SMITH-MAGENIS SYNDROME

* VANDA PHARMACEUTICALS - REACHED AGREEMENT WITH FDA TO RESUBMIT ITS APPLICATION FOR HETLIOZ FOR TREATMENT OF SMITH-MAGENIS SYNDROME

* VANDA PHARMACEUTICALS - TYPE A MEETING RESOLVED OUTSTANDING ISSUES REGARDING FILING OF APPLICATION

* VANDA PHARMACEUTICALS INC - VANDA PLANS TO RESUBMIT AS SOON AS POSSIBLE, SEEKING APPROVAL OF SOLID CAPSULE FORMULATION OF HETLIOZ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below